RAR and RXR modulation in cancer and metabolic disease

被引：437

作者：

Altucci, Lucia

Leibowitz, Mark D.

Ogilvie, Kathleen M.

de Lera, Angel R.

Gronemeyer, Hinrich

机构：

[1] Dipartimento di Patologia Generale, Seconda Università degli Studi di Napoli, 80138 Napoli

[2] Ligand Pharmaceuticals Inc., Department of Pharmacology, San Diego, CA 92121

[3] Exelixis Inc., San Diego, CA 92121

[4] Universidade de Vigo, Departamento de Química Orgánica, Facultad de Química

[5] Department of Cancer Biology, Institut de Génétique et de Biologie Moléculaire et Cellulaire, 67404 Illkirch Cedex

来源：

NATURE REVIEWS DRUG DISCOVERY | 2007年 / 6卷 / 10期

关键词：

D O I：

10.1038/nrd2397

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Retinoic acid receptors (RARs) are ligand-controlled transcription factors that function as heterodimers with retinoid X receptors (RXRs) to regulate cell growth and survival. The success of RAR modulation in the treatment of acute promyelocytic leukaemia (APL) has stimulated considerable interest in the development of RAR and RXR modulators. This has been aided by recent advances in the understanding of the biological role of RARs and RXRs and in the design of selective receptor modulators that might overcome the limitations of current drugs. Here, we discuss the challenges and opportunities for therapeutic strategies based on RXR and RAR modulators, with a focus on cancer and metabolic diseases such as diabetes and obesity.

引用

页码：793 / 810

页数：18

共 187 条

[1] Randomized phase II/III trial of interferon alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell carcinoma:: The European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951) [J].